A. Sato

发表

Hypoxia Imaging Endoscopy Equipped with Laser Light Source from Preclinical Live Animal Study to First-In-Human Subject Research

K. Kaneko, H. Yamaguchi, Takaaki Saito, 2014, PloS one.

Investigation of the Factors Affecting Risk-Based Quality Management of Investigator-Initiated Investigational New-Drug Trials for Unapproved Anticancer Drugs in Japan

A. Sato, Tomohisa Sudo, 2017, Therapeutic innovation & regulatory science.

Effect of novel bright image enhanced endoscopy using blue laser imaging (BLI)

Hiroaki Ikematsu, Yasuhiro Oono, Kazuhiro Kaneko, 2014, Endoscopy International Open.

Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604)

A. Sato, K. Nihei, K. Muro, 2015, Cancer science.

Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial)

H. Mano, S. Nomura, A. Sato, 2020, Clinical Cancer Research.

Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305)

Hideo Nakamura, J. Kuratsu, M. Nagane, 2013, Cancer Chemotherapy and Pharmacology.

BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer

S. Nomura, A. Sato, A. Ohtsu, 2020, ESMO Open.

TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study.

S. Nomura, A. Sato, A. Ohtsu, 2017, The Lancet. Oncology.

A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201).

S. Nomura, A. Sato, K. Muro, 2016, European journal of cancer.

Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer

S. Nomura, A. Sato, A. Ohtsu, 2019, ESMO Open.

A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708).

A. Sato, H. Yamana, M. Shinoda, 2009, Japanese journal of clinical oncology.

Endoscopic submucosal dissection using a new scissors-type electrosurgical knife: a first-in-human feasibility study

K. Kaneko, T. Yano, Y. Oono, 2014, Endoscopy.

A multicenter phase II study of TAS-114 in combination with S-1 in patients with pretreated advanced gastric cancer (EPOC1604)

S. Nomura, A. Sato, D. Takahari, 2020, Gastric Cancer.

Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial.

S. Nomura, A. Sato, T. Kuwata, 2020, The Lancet. Oncology.

Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407)

Y. Einaga, K. Tsuchihashi, H. Saya, 2017, Gastric Cancer.

First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors

S. Nomura, A. Sato, K. Matsushima, 2019, Journal of Immunotherapy for Cancer.

Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).

S. Nomura, A. Sato, T. Kuwata, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial

S. Nomura, A. Sato, A. Ohtsu, 2021, Nature Medicine.

Pertuzumab plus trastuzumab and real-world standard of care (SOC) for patients (pts) with treatment refractory metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) confirmed by tumor tissue or ctDNA analysis (TRIUMPH, EPOC1602).

S. Nomura, A. Sato, A. Ohtsu, 2021 .

Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603).

S. Nomura, A. Sato, T. Kojima, 2019, Journal of Clinical Oncology.

Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303)

S. Nomura, A. Sato, K. Muro, 2017, Esophagus.

Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205)

Y. Einaga, K. Tsuchihashi, H. Saya, 2017, Gastric Cancer.

VOLTAGE: Multicenter phase Ib/II study of nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy (CRT) with capecitabine in patients with locally advanced rectal cancer (LARC).

A. Sato, M. Kojima, T. Yoshino, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602.

A. Sato, H. Yoshikawa, T. Onda, 2008, Japanese journal of clinical oncology.

Phase I trial of GBS‐01 for advanced pancreatic cancer refractory to gemcitabine

S. Nomura, A. Sato, H. Esumi, 2016, Cancer science.

Greater extent of blood‐tumor TCR repertoire overlap is associated with favorable clinical responses to PD‐1 blockade

A. Sato, K. Matsushima, S. Ueha, 2021, Cancer science.

Phase I study of tamibarotene monotherapy in pediatric and young adult patients with recurrent/refractory solid tumors

T. Ushijima, A. Sato, N. Hattori, 2021, Cancer Chemotherapy and Pharmacology.

Prospective trial of biodegradable stents for refractory benign esophageal strictures after curative treatment of esophageal cancer.

K. Kaneko, T. Yano, S. Nomura, 2017, Gastrointestinal endoscopy.

Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.

T. Kohno, Y. Ohe, S. Nomura, 2017, The Lancet. Respiratory medicine.

Final Results of a Safety and Efficacy Trial of Preoperative Sequential Chemoradiation Therapy for the Nonsurgical Treatment of Early Breast Cancer: Japan Clinical Oncology Group Study JCOG0306

H. Iwata, H. Tsuda, H. Mukai, 2013, Oncology.

Efficacy of the NCCV Cocktail‐1 vaccine for refractory pediatric solid tumors: A phase I clinical trial

A. Sato, A. Manabe, A. Hosono, 2019, Cancer science.

TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704)

A. Sato, M. Suzuki, S. Koyama, 2021, Clinical Cancer Research.

Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability–High Locally Advanced Rectal Cancer

A. Sato, M. Kojima, Tsutomu Yoshida, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Randomized controlled trial to evaluate laparoscopic surgery for colorectal cancer: Japan Clinical Oncology Group Study JCOG 0404.

S. Kitano, A. Sato, M. Inomata, 2005, Japanese journal of clinical oncology.

Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer.

A. Sato, M. Kojima, Masaaki Ito, 2020 .

A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): Luret study.

T. Kohno, T. Yamanaka, Y. Ohe, 2016 .

TAS-116, an oral HSP90 inhibitor, in combination with nivolumab in patients with colorectal cancer and other solid tumors: An open-label, dose-finding, and expansion phase Ib trial (EPOC1704).

S. Nomura, A. Sato, H. Nishikawa, 2020 .

A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone as treatment for liver metastasis from colorectal cancer: Japan Clinical Oncology Group Study JCOG0603.

Y. Inaba, A. Sato, Tomoyuki Kato, 2009, Japanese journal of clinical oncology.

Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.

S. Nomura, A. Sato, A. Ohtsu, 2018 .

Survival outcomes and functional results of VOLTAGE-A: Preoperative chemoradiotherapy (CRT) and consolidation nivolumab (nivo) in patients (pts) with both microsatellite stable (MSS) and microsatellite instability–high (MSI-H) locally advanced rectal cancer (LARC).

A. Sato, M. Kojima, T. Yoshino, 2023, Journal of Clinical Oncology.

Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer.

T. Kohno, S. Nomura, A. Sato, 2021, Lung cancer.

Change in plasma lactate concentration during arctigenin administration in a phase I clinical trial in patients with gemcitabine-refractory pancreatic cancer

S. Nomura, A. Sato, H. Esumi, 2018, PloS one.

Final analysis of a safety and efficacy trial of preoperative sequential chemoradiation therapy for the nonsurgical treatment (NST) in early breast cancer (EBC): Japan Clinical Oncology Group Trial (JCOG0306).

H. Tsuda, H. Mukai, A. Sato, 2010 .

Artificial intelligence (AI)-powered HER2 quantification continuous score (QCS) and tumor microenvironment (TME) analysis in HER2-amplified metastatic colorectal cancer (mCRC) treated with pertuzumab plus trastuzumab.

R. Yamashita, A. Sato, C. Ock, 2023, JCO Global Oncology.

Regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer: an open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603).

S. Nomura, A. Sato, T. Kojima, 2019, Annals of Oncology.

Fibroblast inhibition by tocilizumab enabled gemcitabine/nab‐paclitaxel rechallenge for pancreatic cancer

K. Yamaguchi, A. Sato, H. Imaoka, 2023, Cancer science.